Advertisement

BioDrugs

, Volume 13, Issue 4, pp 227–231 | Cite as

Melanoma Vaccines in Development

Looking to the Future
  • Reinhard Dummer
  • Frank O. Nestle
Leading Article

Abstract

There is a body of evidence indicating that melanoma is an antigenic tumour. Since the efficacy of standard therapy in advanced stages of melanoma is rather poor, experimental immunotherapy aims to target this aggressive neoplasm. After the identification of several melanoma antigens, vaccination trials have been initiated in patients with metastatic disease using peptides, dendritic cells and gene therapy approaches including viral vectors or naked DNA. If the problems in inducing a constant and potent T cell response are solved, the stability of melanoma antigens and their presentation will decide whether these treatment approaches will reach significant relevance in daily clinical practice.

Keywords

Melanoma Tumour Antigen Autologous Tumour Cell Melanoma Antigen Lymphatic Organ 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Grants from the Cancer League Zürich and the Swiss Cancer League to F.O. Nestle, and from the Swiss Science Foundation to R. Dummer (no. 31-55727.98), are gratefully acknowledged.

References

  1. 1.
    Dummer R, Nestle FO, Burg G. Therapie des kutanen Melanoms. Ther Umschau 1998; 55: 509–14Google Scholar
  2. 2.
    Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18: 267–8PubMedCrossRefGoogle Scholar
  3. 3.
    Nestle FO, Burg G, Dummer R. New perspectives on immuno-biology and immunotherapy of melanoma. Immunol Today 1999; 20: 5–7PubMedCrossRefGoogle Scholar
  4. 4.
    Geertsen R, Hofbauer G, Kamarashev J, et al. Immune escape mechanisms in malignant melanoma. Int J Mol Med 1999; 3: 49–57PubMedGoogle Scholar
  5. 5.
    Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988; 319: 1676–80PubMedCrossRefGoogle Scholar
  6. 6.
    Pardoll DM. Cancer vaccines. Nat Med 1998; 4: 525–31PubMedCrossRefGoogle Scholar
  7. 7.
    Livingston P. Ganglioside vaccines with emphasis on GM2. Semin Oncol 1999; 25: 636–45Google Scholar
  8. 8.
    Zinkernagel RM, Ehl S, Aichele P, et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997; 156: 199–209PubMedCrossRefGoogle Scholar
  9. 9.
    Speiser DE, Miranda R, Zakarian A, et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997; 186: 645–53PubMedCrossRefGoogle Scholar
  10. 10.
    Dummer R, Davis-Daneshfar A, Döhring C, et al. Strategien zur Gentherapie des Melanoms. Hautarzt 1995; 46: 305–8PubMedCrossRefGoogle Scholar
  11. 11.
    Hofbauer GF, Schaefer C, Noppen C, et al. MAGE-3 immuno-reactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151: 1549–53PubMedGoogle Scholar
  12. 12.
    Hofbauer GF, Kamarashev J, Geertsen R, et al. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol 1998; 25: 204–9PubMedCrossRefGoogle Scholar
  13. 13.
    Marchand M, vanBaren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219–30PubMedCrossRefGoogle Scholar
  14. 14.
    Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macro-phage-colony-stimulating factor enhances immune responses to melanoma associated peptides in vivo. Int J Cancer 1996; 67: 54–62PubMedCrossRefGoogle Scholar
  15. 15.
    Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183–7PubMedCrossRefGoogle Scholar
  16. 16.
    Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328–32PubMedCrossRefGoogle Scholar
  17. 17.
    Toes RE, van der Voort El, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998; 160: 4449–56PubMedGoogle Scholar
  18. 18.
    Toes RE, Offringa R, Blom RJ, et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 1996; 93: 7855–60PubMedCrossRefGoogle Scholar
  19. 19.
    Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5: 774–9PubMedCrossRefGoogle Scholar
  20. 20.
    Lee DJ, Corr M, Carson DA. Control of immune responses by gene immunization. Ann Med 1998; 30: 460–8PubMedCrossRefGoogle Scholar
  21. 21.
    Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 19: 273(5273): 352–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Department of DermatologyUniversity HospitalZurichSwitzerland

Personalised recommendations